CORRECTION - Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

a week ago

GAITHERSBURG, Md., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- In a release issued under the same headline earlier today by Altimmune, Inc. ( Nasdaq:ALT ) , please note that the reduction of visceral adipose tissue ( VAT ) at Week 48 has been corrected from 25.6% to 28.3% and the reduction of ...

Ticker	Sentiment	Impact
ALT	Neutral	27 %